547 related articles for article (PubMed ID: 30416504)
1. CD169
Grabowska J; Lopez-Venegas MA; Affandi AJ; den Haan JMM
Front Immunol; 2018; 9():2472. PubMed ID: 30416504
[TBL] [Abstract][Full Text] [Related]
2. Functional CD169 on Macrophages Mediates Interaction with Dendritic Cells for CD8
van Dinther D; Veninga H; Iborra S; Borg EGF; Hoogterp L; Olesek K; Beijer MR; Schetters STT; Kalay H; Garcia-Vallejo JJ; Franken KL; Cham LB; Lang KS; van Kooyk Y; Sancho D; Crocker PR; den Haan JMM
Cell Rep; 2018 Feb; 22(6):1484-1495. PubMed ID: 29425504
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Protein and Peptide Targeting for the Development of a CD169-Based Vaccination Strategy Against Melanoma.
van Dinther D; Veninga H; Revet M; Hoogterp L; Olesek K; Grabowska J; Borg EGF; Kalay H; van Kooyk Y; den Haan JMM
Front Immunol; 2018; 9():1997. PubMed ID: 30237798
[TBL] [Abstract][Full Text] [Related]
4. Selective tumor antigen vaccine delivery to human CD169
Affandi AJ; Grabowska J; Olesek K; Lopez Venegas M; Barbaria A; Rodríguez E; Mulder PPG; Pijffers HJ; Ambrosini M; Kalay H; O'Toole T; Zwart ES; Kazemier G; Nazmi K; Bikker FJ; Stöckl J; van den Eertwegh AJM; de Gruijl TD; Storm G; van Kooyk Y; den Haan JMM
Proc Natl Acad Sci U S A; 2020 Nov; 117(44):27528-27539. PubMed ID: 33067394
[TBL] [Abstract][Full Text] [Related]
5. Targeted delivery of lipid antigen to macrophages via the CD169/sialoadhesin endocytic pathway induces robust invariant natural killer T cell activation.
Kawasaki N; Vela JL; Nycholat CM; Rademacher C; Khurana A; van Rooijen N; Crocker PR; Kronenberg M; Paulson JC
Proc Natl Acad Sci U S A; 2013 May; 110(19):7826-31. PubMed ID: 23610394
[TBL] [Abstract][Full Text] [Related]
6. The CD169 sialoadhesin molecule mediates cytotoxic T-cell responses to tumour apoptotic vesicles.
Black LV; Saunderson SC; Coutinho FP; Muhsin-Sharafaldine MR; Damani TT; Dunn AC; McLellan AD
Immunol Cell Biol; 2016 May; 94(5):430-8. PubMed ID: 26647968
[TBL] [Abstract][Full Text] [Related]
7. Tumor Necrosis Factor-Mediated Survival of CD169
Shinde PV; Xu HC; Maney SK; Kloetgen A; Namineni S; Zhuang Y; Honke N; Shaabani N; Bellora N; Doerrenberg M; Trilling M; Pozdeev VI; van Rooijen N; Scheu S; Pfeffer K; Crocker PR; Tanaka M; Duggimpudi S; Knolle P; Heikenwalder M; Ruland J; Mak TW; Brenner D; Pandyra AA; Hoell JI; Borkhardt A; Häussinger D; Lang KS; Lang PA
J Virol; 2018 Feb; 92(3):. PubMed ID: 29142134
[TBL] [Abstract][Full Text] [Related]
8. Dendritic cells from bench to bedside and back.
Adema GJ
Immunol Lett; 2009 Feb; 122(2):128-30. PubMed ID: 19121337
[TBL] [Abstract][Full Text] [Related]
9. Interferon-inducible mechanism of dendritic cell-mediated HIV-1 dissemination is dependent on Siglec-1/CD169.
Puryear WB; Akiyama H; Geer SD; Ramirez NP; Yu X; Reinhard BM; Gummuluru S
PLoS Pathog; 2013; 9(4):e1003291. PubMed ID: 23593001
[TBL] [Abstract][Full Text] [Related]
10. CD169-mediated trafficking of HIV to plasma membrane invaginations in dendritic cells attenuates efficacy of anti-gp120 broadly neutralizing antibodies.
Akiyama H; Ramirez NG; Gudheti MV; Gummuluru S
PLoS Pathog; 2015 Mar; 11(3):e1004751. PubMed ID: 25760631
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Significance of CD169+ Lymph Node Sinus Macrophages in Patients with Malignant Melanoma.
Saito Y; Ohnishi K; Miyashita A; Nakahara S; Fujiwara Y; Horlad H; Motoshima T; Fukushima S; Jinnin M; Ihn H; Takeya M; Komohara Y
Cancer Immunol Res; 2015 Dec; 3(12):1356-63. PubMed ID: 26297710
[TBL] [Abstract][Full Text] [Related]
12. CD169 Defines Activated CD14
Affandi AJ; Olesek K; Grabowska J; Nijen Twilhaar MK; Rodríguez E; Saris A; Zwart ES; Nossent EJ; Kalay H; de Kok M; Kazemier G; Stöckl J; van den Eertwegh AJM; de Gruijl TD; Garcia-Vallejo JJ; Storm G; van Kooyk Y; den Haan JMM
Front Immunol; 2021; 12():697840. PubMed ID: 34394090
[TBL] [Abstract][Full Text] [Related]
13. Deficiency of the B cell-activating factor receptor results in limited CD169+ macrophage function during viral infection.
Xu HC; Huang J; Khairnar V; Duhan V; Pandyra AA; Grusdat M; Shinde P; McIlwain DR; Maney SK; Gommerman J; Löhning M; Ohashi PS; Mak TW; Pieper K; Sic H; Speletas M; Eibel H; Ware CF; Tumanov AV; Kruglov AA; Nedospasov SA; Häussinger D; Recher M; Lang KS; Lang PA
J Virol; 2015 May; 89(9):4748-59. PubMed ID: 25673724
[TBL] [Abstract][Full Text] [Related]
14. CD169+ macrophages at the crossroads of antigen presentation.
Martinez-Pomares L; Gordon S
Trends Immunol; 2012 Feb; 33(2):66-70. PubMed ID: 22192781
[TBL] [Abstract][Full Text] [Related]
15. CD169+ macrophages are sufficient for priming of CTLs with specificities left out by cross-priming dendritic cells.
Bernhard CA; Ried C; Kochanek S; Brocker T
Proc Natl Acad Sci U S A; 2015 Apr; 112(17):5461-6. PubMed ID: 25922518
[TBL] [Abstract][Full Text] [Related]
16. CD169+ Subcapsular Macrophage Role in Antigen Adjuvant Activity.
Lisk C; Yuen R; Kuniholm J; Antos D; Reiser ML; Wetzler LM
Front Immunol; 2021; 12():624197. PubMed ID: 33815376
[TBL] [Abstract][Full Text] [Related]
17. Targeted Delivery of Antigen to Activated CD169
Edgar LJ; Kawasaki N; Nycholat CM; Paulson JC
Cell Chem Biol; 2019 Jan; 26(1):131-136.e4. PubMed ID: 30393066
[TBL] [Abstract][Full Text] [Related]
18. Self- and nonself-recognition by C-type lectins on dendritic cells.
Geijtenbeek TB; van Vliet SJ; Engering A; 't Hart BA; van Kooyk Y
Annu Rev Immunol; 2004; 22():33-54. PubMed ID: 15032573
[TBL] [Abstract][Full Text] [Related]
19. A Protective Role for the Lectin CD169/Siglec-1 against a Pathogenic Murine Retrovirus.
Uchil PD; Pi R; Haugh KA; Ladinsky MS; Ventura JD; Barrett BS; Santiago ML; Bjorkman PJ; Kassiotis G; Sewald X; Mothes W
Cell Host Microbe; 2019 Jan; 25(1):87-100.e10. PubMed ID: 30595553
[TBL] [Abstract][Full Text] [Related]
20. Platelets interact with CD169
Grabowska J; Léopold V; Olesek K; Nijen Twilhaar MK; Affandi AJ; Brouwer MC; Jongerius I; Verschoor A; van Kooten C; van Kooyk Y; Storm G; van 't Veer C; den Haan JMM
Front Immunol; 2023; 14():1290272. PubMed ID: 38054006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
